Also found in: Dictionary.



Pharmacologic class: Folic acid antagonist

Therapeutic class: Antiprotozoal, antimalarial

Pregnancy risk category C


Inhibits reduction of dihydrofolic acid to tetrahydrofolic acid (folinic acid) by binding to and reversibly inhibiting dihydrofolate reductase


Tablets: 25 mg

Indications and dosages

To control plasmodia transmission and suppress susceptible strains Adults and children ages 10 and older: 25 mg P.O. daily for 2 days, given with a sulfonamide


Adults: Initially, 50 to 75 mg P.O. daily for 1 to 3 weeks, given with a sulfonamide. Depending on response and tolerance, reduce dosages of both drugs by 50% and continue therapy for 4 to 5 more weeks.

Children: 1 mg/kg P.O. daily in two equally divided doses for 2 to 4 days, then reduced to 0.5 mg/kg/day for approximately 1 month. Alternatively, 2 mg/kg (up to 100 mg) P.O. daily in two equally divided doses for 3 days, then 1 mg/kg (up to 25 mg) in two equally divided doses for 4 weeks, given with sulfadiazine for 4 weeks.

Prophylaxis of malaria caused by susceptible plasmodia strains

Adults and children older than age 10: 25 mg P.O. weekly

Children ages 4 to 10: 12.5 mg P.O. weekly

Infants and children younger than age 4: 6.25 mg P.O. weekly

Off-label uses

• Isosporiasis

• Prophylaxis of Pneumocystis jiroveci pneumonia


• Hypersensitivity to drug

• Megaloblastic anemia caused by folate deficiency

• Concurrent folate antagonist therapy


Use cautiously in:

• anemia, bone marrow depression, hepatic or renal impairment, G6PD deficiency

• history of seizures

• patients more than 16 weeks pregnant

• breastfeeding patients.


• Administer with meals.

• When giving tablets to young children, crush them and administer as oral suspension in water, cherry syrup, or sweetened solution.

• Know that because of worldwide resistance to pyrimethamine, its use alone to prevent or treat acute malaria is no longer recommended.

• Be aware that fixed combination of pyrimethamine and sulfadoxine is available and has been used for uncomplicated mild to moderate malaria caused by chloroquineresistant Plasmodium falciparum and for presumptive self-treatment by travelers.

Adverse reactions

CNS: headache, light-headedness, insomnia, malaise, depression, seizures

CV: arrhythmias

EENT: dry throat

GI: nausea, vomiting, diarrhea, anorexia, atrophic glossitis

GU: hematuria

Hematologic: megaloblastic anemia, leukopenia, pancytopenia, thrombocytopenia

Metabolic: hyperphenylalaninemia

Respiratory: pulmonary eosinophilia

Skin: pigmentation changes, dermatitis, erythema multiforme, toxic epidermal necrolysis, Stevens-Johnson syndrome

Other: fever, anaphylaxis


Drug-drug. Lorazepam: hepatotoxicity Myelosuppressants (including antineoplastics): increased risk of bone marrow depression

Drug-diagnostic tests. Platelets, white blood cells: decreased counts

Patient monitoring

• Monitor CBC. Watch for evidence of blood dyscrasias.

• Assess for signs and symptoms of folic acid deficiency.

• Closely monitor neurologic and cardiovascular status. Stay alert for seizures and arrhythmias.

Watch for evidence of erythema multiforme, including sore throat, cough, mouth sores, rash, iritic lesions, and fever. Report early signs before condition can progress to Stevens-Johnson syndrome.

Patient teaching

• Advise patient to take with meals.

Tell patient to discontinue drug and contact prescriber at first sign of rash.

• Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration and alertness.

• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.



A trademark for the drug pyrimethamine.


a trademark for an antimalarial (pyrimethamine).


A brand name for PYRIMETHAMINE.
References in periodicals archive ?
ca0f5808e953) he released a video threatening Wu-Tang Clan member Ghostface Killah for criticizing his decision to raise Daraprim prices.
Gottlieb has said in the past that the main problem behind high drug prices isn't the cost of new, specialty drugs but instead old drugs whose sellers can indiscriminately raise prices because there isn't enough competition from generics, like in the case of Daraprim.
If a drug's patent has expired, as was the case with Daraprim, Bayh-Dole no longer applies.
Daraprim, the drug in question, had gone from costing around $13.
Daraprim, the company that bought the rights to the drug and increased its price, is just the latest entry in the ongoing debate about whether some drugs are effective enough to justify the cost.
Martin Shkreli, CEO of Turing Pharmaceuticals caused a huge stir when he raised the price of Daraprim from $13.
Hedge fund manager Shkreli, the former CEO of Turing Pharmaceuticals, who infamously raised the price of Daraprim from $13.
In mid-September of 2015, Turing Pharmaceuticals ("Turing"), a start-up pharmaceutical company run by former hedge fund manager Martin Shkreli ("Shkreli"), made international headlines after purchasing the rights to a little-known drug named Daraprim and increasing its price by 5,000 percent overnight.
Shkreli is reviled for buying the rights to AIDS drug Daraprim and raising its price by 5,456 percent to $750.
Earlier, Shkreli invoked his Fifth Amendment right against self-incrimination and declined to answer questions from lawmakers about drug price increases he engineered, such as hiking the price of 62-year-old Daraprim to $750 a pill from $13.
Juxtapose the price of the iPhone with the recent story of Turing Pharmaceuticals, whose CEO Martin Shkreli recently raised the price 50-fold of the old antiparasitic medicine Daraprim and was quickly labelled the "most-hated man in America.